The NeoThetis Pan-Cancer panel analyses 80 genes associated with different types of cancers. It can help identify genetic alterations that can be responsible for cancer development and therapy resistance in solid tumors. The clinical significance of the genes tested has been previously emphasized by professional bodies including NCCN and ESMO. Depending on the type of the cancer and the genetic alterations identified, different FDA/EMA approved drugs as well as eligible clinical trials are available.
Microsatellite instability (MSI) immunotherapy biomarker is also tested in this panel. FDA/EMA approved immunotherapies, such as pembrolizumab, are also available for patients with MSI-high status depending on their type of cancer.
How many genes are tested in this panel?
Recommendations by professional bodies
Professional bodies such as ESMO recommend liquid biopsy genetic testing for different types of cancer and in different circumstances; such as when tissue biopsy is not feasible or when fast turnaround results are required (Pascual et al., 2022; ESMO recommendations).
For more details on recommendations please visit our cancer-specific panels.
References and more information:
• Pascual J, Attard G, Bidard FC, Curigliano G, De Mattos-Arruda L, Diehn M, Italiano A, Lindberg J, Merker JD, Montagut C, Normanno N, Pantel K, Pentheroudakis G, Popat S, Reis-Filho JS, Tie J, Seoane J, Tarazona N, Yoshino T, Turner NC. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2022 Aug;33(8):750-768. doi: 10.1016/j.annonc.2022.05.520. Epub 2022 Jul 6. PMID: 35809752.